Affinity Asset Advisors »

Nuvalent Inc-a shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Nuvalent Inc-a (NUVL) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Nuvalent Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Nuvalent Inc-a held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nuvalent Inc-a by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $2.3M 50k 45.97

More positions owned by Affinity Asset Advisors

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Apogee Therapeutics (APGE)
Establishment Labs Holdings Ord (ESTA)
Cymabay Therapeutics
Immunovant (IMVT)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Madrigal Pharmaceuticals (MDGL)
Xenon Pharmaceuticals (XENE)
Alkermes SHS Call Option (ALKS)
Kura Oncology (KURA)
Astria Therapeutics (ATXS)
Morphic Hldg (MORF)

View all positions for Affinity Asset Advisors

Top funds holding Nuvalent Inc-a

Deerfield Management Company
Paradigm Biocapital Advisors
Vanguard Group
Perceptive Advisors
Fairmount Funds Management
Commodore Capital
Boxer Capital
T. Rowe Price Associates
Wellington Management Company
D. E. Shaw & Co
Lord, Abbett & Co
Ikarian Capital
Soleus Capital Management
Fred Alger Management
Dimensional Fund Advisors

View all funds holding Nuvalent Inc-a